Keiran Raine

Keiran Raine

Auto-generated profile, based on publicly available information

Keiran Raine

Cancer Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Cambridge, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2017 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
HDHelen Davies
Helen Davies
DGDominik Glodzik
Dominik Glodzik
SMSandro Morganella
Sandro Morganella
LYLucy R Yates
Lucy R Yates
JSJohan Staaf
Johan Staaf
SNSerena Nik-Zainal
Serena Nik-Zainal

22 June 2015 in Nature Medicine
Verified
Journal Article
Open access
PDF file
LYLucy R Yates
Lucy R Yates
MGMoritz Gerstung
Moritz Gerstung
SKStian Knappskog
Stian Knappskog
Christine DesmedtChristine Desmedt
Christine Desmedt
GGGunes Gundem
Gunes Gundem
PCPeter J Campbell
Peter J Campbell
Whole-genome and targeted sequencing of multiple sections of each of 50 tumors reveals varying degrees of subclonal diversification and genomic heterogeneity. The sequencing of cancer genomes may enable tailoring of therapeutics to the underlying biological abnormalities driving a particular patient's tumor. However, sequencing-based strategies rely heavily on representative sampling of tumors. To understand the subclonal structure of primary breast cancer, we applied whole-genome and targeted sequencing to multiple samples from each of 50 patients' tumors (303 samples in total). The extent of subclonal diversification varied among cases and followed spatial patterns. No strict temporal order was evident, with point mutations and rearrangements affecting the most common breast cancer genes, including PIK3CA, TP53, PTEN, BRCA2 and MYC, occurring early in some tumors and late in others. In 13 out of 50 cancers, potentially targetable mutations were subclonal. Landmarks of disease progression, such as resistance to chemotherapy and the acquisition of invasive or metastatic potential, arose within detectable subclones of antecedent lesions. These findings highlight the importance of including analyses of subclonal structure and tumor evolution in clinical trials of primary breast cancer.

5 February 2020 in Nature Genetics
Verified
Journal Article
Open access
PDF file
BRBernardo Rodriguez-Martin
Bernardo Rodriguez-Martin
EAEva G. Alvarez
Eva G. Alvarez
ABAdrian Baez-Ortega
Adrian Baez-Ortega
JZJorge Zamora
Jorge Zamora
FSFran Supek
Fran Supek
JTJose M. C. Tubio
Jose M. C. Tubio
About half of all cancers have somatic integrations of retrotransposons. Here, to characterize their role in oncogenesis, we analyzed the patterns and mechanisms of somatic retrotransposition in 2,954 cancer genomes from 38 histological cancer subtypes within the framework of the Pan-Cancer Analysis of Whole Genomes (PCAWG) project. We identified 19,166 somatically acquired retrotransposition events, which affected 35% of samples and spanned a range of event types. Long interspersed nuclear element (LINE-1; L1 hereafter) insertions emerged as the first most frequent type of somatic structural variation in esophageal adenocarcinoma, and the second most frequent in head-and-neck and colorectal cancers. Aberrant L1 integrations can delete megabase-scale regions of a chromosome, which sometimes leads to the removal of tumor-suppressor genes, and can induce complex translocations and large-scale duplications. Somatic retrotranspositions can also initiate breakage–fusion–bridge cycles, leading to high-level amplification of oncogenes. These observations illuminate a relevant role of 22 L1 retrotransposition in remodeling the cancer genome, with potential implications for the development of human tumors.

2 March 2015 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TGthe ICGC Prostate Group
the ICGC Prostate Group
CCColin S Cooper
Colin S Cooper
RERosalind Eeles
Rosalind Eeles
DWDavid Wedge
David Wedge
PLPeter Van Loo
Peter Van Loo
DNDavid E Neal
David E Neal
Colin Cooper and colleagues report genome-wide sequences of multiple samples of multifocal cancer and morphologically normal tissue from the prostates of three men. They found high levels of mutations in morphologically normal tissue distant from the cancer, consistent with field effects. Genome-wide DNA sequencing was used to decrypt the phylogeny of multiple samples from distinct areas of cancer and morphologically normal tissue taken from the prostates of three men. Mutations were present at high levels in morphologically normal tissue distant from the cancer, reflecting clonal expansions, and the underlying mutational processes at work in morphologically normal tissue were also at work in cancer. Our observations demonstrate the existence of ongoing abnormal mutational processes, consistent with field effects, underlying carcinogenesis. This mechanism gives rise to extensive branching evolution and cancer clone mixing, as exemplified by the coexistence of multiple cancer lineages harboring distinct ERG fusions within a single cancer nodule. Subsets of mutations were shared either by morphologically normal and malignant tissues or between different ERG lineages, indicating earlier or separate clonal cell expansions. Our observations inform on the origin of multifocal disease and have implications for prostate cancer therapy in individual cases.

2 October 2020 in Science
Verified
Journal Article
Closed access
ALAndrew R. J. Lawson
Andrew R. J. Lawson
FAFederico Abascal
Federico Abascal
TCTim H. H. Coorens
Tim H. H. Coorens
YHYvette Hooks
Yvette Hooks
LOLaura O’nEill
Laura O’nEill
IMIñigo Martincorena
Iñigo Martincorena
Genetic profiles of the bladder: Depending on the environment of the individual, the human bladder can be exposed to carcinogens as they are flushed through the body. Lawson et al. and Li et al. examined the genetic composition of laser-dissected microbiopsies from normal and cancer cells collected from the urothelium, a specialized epithelium lining the lower urinary tract (see the Perspective by Rozen). These complementary studies identified the mutational landscape of bladder urothelium through various sequencing strategies and identified high mutational heterogeneity within and between individuals and tumors. Both studies identified mutational profiles related to specific carcinogens such as aristolochic acid and the molecules found in tobacco. These studies present a comprehensive description of the diverse mutational landscape of the human bladder in health and disease, unraveling positive selection for cancer-causing mutations, a diversity of mutational processes, and large differences across individuals. Science , this issue p. 75 , p. 82 ; see also p. 34

9 December 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
TATyler Alioto
Tyler Alioto
IBIvo Buchhalter
Ivo Buchhalter
SDSophia Derdak
Sophia Derdak
BHBarbara Hutter
Barbara Hutter
MEMatthew D. Eldridge
Matthew D. Eldridge
IGIvo G. Gut
Ivo G. Gut
As whole-genome sequencing for cancer genome analysis becomes a clinical tool, a full understanding of the variables affecting sequencing analysis output is required. Here using tumour-normal sample pairs from two different types of cancer, chronic lymphocytic leukaemia and medulloblastoma, we conduct a benchmarking exercise within the context of the International Cancer Genome Consortium. We compare sequencing methods, analysis pipelines and validation methods. We show that using PCR-free methods and increasing sequencing depth to ∼100 × shows benefits, as long as the tumour:control coverage ratio remains balanced. We observe widely varying mutation call rates and low concordance among analysis pipelines, reflecting the artefact-prone nature of the raw data and lack of standards for dealing with the artefacts. However, we show that, using the benchmark mutation set we have created, many issues are in fact easy to remedy and have an immediate positive impact on mutation detection accuracy.